Back to search results

A Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults

This study is testing a Semaglutide Nasal Spray (WL1006) for adults who are overweight or obese. Researchers want to see how safe it is, how well your body handles it (tolerability), and how the medicine moves through your body (pharmacokinetics). They will compare the nasal spray to a placebo (an inactive substance) and to Semaglutide Injection (Wegovy®), which is already approved. You might be able to join if you are between 18 and 65 years old and have a Body Mass Index (BMI) between 27.0 and 35.0. The study aims to enroll 60 participants, but its current recruitment status is unclear.

Study design
This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 60 participants, but the phase of the study is not specified.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The study will track how the medicine moves through your body for up to 36 days after administration.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07465965

A Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults

Recruiting
PHASE1Ages 18–65InterventionalTreatment
Shanghai World Leader Pharmaceutical Co., Ltd.
~60 participants
Updated 2026-03-12 on ClinicalTrials.gov
What's tested:Semaglutide Nasal SprayPlaceboSemaglutide Injection

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Maximum Plasma Concentration (Cmax)
Measured over Day 1 to Day 36 after administration
+35 more outcomes measured

Conditions

Overweight
Obesity

Explore related trials

ObesityOverweight

Where it's being run

1 sites across 1 states
New Jersey1

Who to contact

Guiyi Huang, Master
[email protected]
0086-18640027113
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

Systemic corticosteroid therapy (intravenous or oral) for \>1 week
Tricyclic antidepressants (e.g., imipramine, amitriptyline, doxepin)
Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, paroxetine, sertraline, fluvoxamine)
Antipsychotics/antiepileptics (e.g., imipramine, amitriptyline, mirtazapine, phenelzine, chlorpromazine HCl, clozapine, olanzapine, valproate derivatives, lithium preparations, thioridazine)
Antihistamines (e.g., cyproheptadine, ketotifen, astemizole). 5. Any investigational drugs, vaccines, or medical devices. 5. Laboratory abnormalities at screening meeting any of the following:

What this trial measures

  • Maximum Plasma Concentration (Cmax)Day 1 to Day 36 after administration
  • Time to maximum concentration(Tmax)Day 1 to Day 36 after administration
  • Area under the concentration-time curve from time 0 to time t (AUC0-t)Day 1 to Day 36 after administration
  • Area under the concentration-time curve from time 0 to infinity(AUC0-∞)Day 1 to Day 36 after administration
  • Percentage of AUC extrapolated(AUC%Extrap)Day 1 to Day 36 after administration
  • Elimination half-life / Terminal half-life(t1/2)Day 1 to Day 36 after administration
  • Apparent volume of distribution during terminal phase, adjusted for bioavailability (Vz/F)Day 1 to Day 36 after administration
  • Apparent clearance, adjusted for bioavailability(CL/F)Day 1 to Day 36 after administration
  • Terminal elimination rate constant(λz)Day 1 to Day 36 after administration
  • Absolute bioavailability(F)Day 1 to Day 36 after administration
  • Incidence and severity of treatment emergent adverse events (TEAEs)Day 1 to Day 36 after administration
  • 12-Lead-ECGs(Electrocardiograms )Day 1 to Day 36 after administration
  • TemperatureDay 1 to Day 36 after administration
  • PulseDay 1 to Day 36 after administration
  • Respiratory rateDay 1 to Day 36 after administration
  • Blood pressureDay 1 to Day 36 after administration
  • UrinalysisDay 1 to Day 36 after administration
  • Blood biochemistryDay 1 to Day 36 after administration

    Alanine aminotransferase, aspartate aminotransferase, total bilirubin, direct bilirubin, γ-glutamyl transferase, alkaline phosphatase, total protein, albumin, urea, uric acid, creatinine, calcium, chloride, potassium, sodium, phosphorus, total cholesterol, triglycerides, fasting blood glucose, creatine kinase, lactate dehydrogenase, amylase, lipase.

  • Thyroid functionDay 1 to Day 36 after administration

    Thyroid-stimulating hormone, total tri-iodothyronine, total thyroxine, free tri-iodothyronine, free thyroxine

  • Virology testDay 1 to Day 36 after administration
  • Urine pregnancy testDay 1 to Day 36 after administration
  • Physical examination, includes: head, ears, eyes, nose and throat, skin, lymph nodes, neck, chest, abdomen, heart, cardiovascular, musculoskeletal system/extremities, neurological system and body weight.Day 1 to Day 4 after administration
  • HemoglobinDay 1 to Day 36 after administration
  • HematocritDay 1 to Day 36 after administration
  • Red blood cell countDay 1 to day 36
  • White blood cell countDay 1 to day36
  • Platelet countDay 1 to day 36
  • Neutrophil percentageday 1 to day 36
  • Eosinophil percentageday 1 to day 36
  • Basophil percentageday 1 to day 36
  • Monocyte percentageday 1 to day 36
  • Lymphocyte percentageday 1 to day 36
  • Activated partial thromboplastin timeDay 1 to day 36
  • Prothrombin timeday 1 to day 36
  • Fibrinogenday 1 to day 36
  • Thrombin timeday 1 to day 36